RxDoctor Payments Data

Wayne Karaki, MD

Internal Medicine · Tyler, TXNPI 1871582924

Payments from drug & device makers

$2,917in general payments, 2019–2025

Across 154 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$301
  • Novo Nordisk$280
  • Medtronic$250
  • Corcept Therapeutics$239
  • Bayer$198
  • Dexcom, Inc.$165
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,917100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,917 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$91,862
Medicare patients
285
Services billed
1,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide217$242,654
EliquisApixaban112$122,604
MounjaroTirzepatide100$105,513
JardianceEmpagliflozin88$89,152
JanuviaSitagliptin Phosphate69$80,533
XareltoRivaroxaban56$55,544
BiktarvyBictegrav/Emtricit/Tenofov Ala12$42,252
FarxigaDapagliflozin Propanediol37$40,845
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$34,026
TrulicityDulaglutide26$30,197
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$24,155
LinzessLinaclotide13$19,845
Repatha SureclickEvolocumab22$18,164
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen533$16,121
Lantus SolostarInsulin Glargine,hum.Rec.Anlog61$15,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$280$242,654217 claims
Lilly USA, LLCMounjaro, Trulicity$154$135,710126 claims
Boehringer IngelheimJardiance, Combivent Respimat$114$98,896108 claims
MerckJanuvia$18$80,53369 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$14$50,311107 claims
AstraZenecaFarxiga, Symbicort$28$48,68065 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →